期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

5例HBV前C区1896位点和/或BCP1762、1764位点变异对聚乙二醇干扰素α2a早期应答的影响 被引量：2

下载PDF
导出
摘要 目的探讨HBV前C区1896位点和/或BCP1762、1764位点变异对聚乙二醇干扰素α2a早期应答的影响。方法选择5例HBV PC1896和/或BCP1762、1764位点发生变异的慢性乙型肝炎患者,使用聚乙二醇干扰素α2a和/或核苷酸类似物抗病毒治疗,观察患者治疗12周、24周、48周时HBs Ag、HBe Ag、HBV DNA、ALT的变化。结果 5例患者使用聚乙二醇干扰素α2a和/或核苷酸类似物抗病毒治疗后12周、24周均发生了应答。结论 HBV PC1896和/或BCP1762、1764位点发生变异作为亚洲人群聚乙二醇干扰素α2a治疗取得早期应答的预测因素。
作者 胡晨波 金宏慧 李仲平 陈晓蓉
机构地区 上海市浦东新区南华医院肝病科 上海市公共卫生临床中心
出处 《肝脏》 2015年第4期310-312,共3页 Chinese Hepatology
基金 浦东新区卫生系统优秀青年医学人才培养(PWRq2012-05) 上海市浦东新区卫生和计划生育委员会科技发展专项基金资助(PW2014A-60)
关键词 乙型肝炎病毒 前C区 基本核心启动子 变异 聚乙二醇干扰素
分类号 R512.62 [医药卫生—内科学]
  • 相关文献

参考文献10

  • 1Sonneveld MJ, Rijckborst V, Zeuzem S, et al. Presence of precore and core promoter mutants limits the probability of response to peglnterferon in hepatitis B e antigen-positive chronic hepatitis B. Hepatology, 2012, 56:67-75.
  • 2贾继东,李兰娟.慢性乙型肝炎防治指南（2010年版）[J].中华肝脏病杂志,2011,19(1):13-24. 被引量：3212
  • 3Tseng TC, Kao JH, Chen DS. et al. Peginterferon alia in the treatment of chronic Hepatitis B. Expert Opin Biol Ther, 2014, 14:995-1006.
  • 4Choi JW, Ahn SH,Park JY, et al. Hepatitis B e antigen-negative mutations in the prefore and core premoter regions in Korean patients. J Med Virol, 2009,81:594- 601.
  • 5Scaglioni PP, Melegari M, Wands JP. Biologic properties of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame. Virology, 1997,233,374-381.
  • 6Heipertz RA Jr, Miller TG, Kelley CM, et al. In vitro study of the effects of preeore and lamivudine-rcsistant mutations on hepatitis B virus replication. J Virot. 2007,81,3068-3076.
  • 7Tong S, Kim KH, Chante C, et al. Hepatitis B Virus e Antigen Variants. Int J Med Sei, 2005,2 : 2-7.
  • 8Mohamadkhani A, Sotoudeh M, Bowden S,et al. Downregulation of HLA class II molecules by GI896A pre-core mutation in chronic hepatitis Bvirus infection. Viral Immunol, 2009, 22: 295-300.
  • 9Moradzadeh M, Tayebi S, Poustehi H, et al. The Possible Role of TLR2 in Chronic Hepatitis B Patients with Preeore Mutation. Adv Virol, 2013, Article ID 780319, 5 pages, 2013. doi= 10. 1155/ 2013/780319.
  • 10Tong MJ, Blatt I.M, Kao JH, et al. Basal core promoter T1762/ A1764 and precore A1896 gene mutations in hepatitis B surface antigen positive hepatocellular carcinoma: a comparison with chronic carriers. Liver Int, 2007,27 : 1356- 1363.

二级参考文献15

共引文献3211

同被引文献31

  • 1黄雁翔,马丽娜,陈新月,李卓,黄云丽,沈成利,马冰.粘病毒抵抗蛋白A和真核细胞起始因子2α调节区2基因多态性与慢性乙型肝炎干扰素治疗效果的相关性[J].中华肝脏病杂志,2007,15(3):187-191. 被引量：12
  • 2Lampertico P,Viganb M ,Cheroni C ,et al. IL28B polymorphisms predict interferen-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B[J]. Hepa- tology,2013,57(3) : 890-896.
  • 3Sonneveld MJ, Wong VW, Woltman AM, et al. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg- positive patients with chronic hepatitis B[J]. Gastroenterology, 2012,142 (3) : 513-520.
  • 4Wu H ,Zhao G, Qian F,et al. Association of IL28B polymorphisms with peginterferon treatment response in Chinese Han patients with HBeAg- positive chronic hepatitis B[J]. Liver Int, 2015,35 (2) : 473-481.
  • 5Holmes JA, Nguyen T, Ratnam D, et al. IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-alpha[J]. J Gastroenterol Hepatol, 2013,28 (5) : 861-866.
  • 6Zhang Q,LapalusM,Asselah T,et al. IFNL3 (IL28B)polymorphism does not predict long-term response to interferontherapy in HBeAg-positive chronic hepatitis B patients[J]. J Viral Hepat ,2014,21 (7) :525-532.
  • 7Tseng TC, Yu ML, Liu C J, et al. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated in- terferon-ot-2a therapy[J]. Antivir Ther, 2011,16 ( 5 ) : 629 -637.
  • 8Wang S, Huang D, Huang D, et al. Interleukin-10 promoter polymorphisms predicts initial response of chronic hepatitis B to interferon alfa[J]. Viral, 2011,8(1) :1-6.
  • 9Kong LN, Qin B, Ma Q, et al. Relationship between hepatitis B virus geno- type B and C and response to interferon therapy in HBeAg positive chronic hepatitis B patients :a meta-analysis[J]. J Gastroenterol Hepatol, 2014,29 (7) :1387-1395.
  • 10Sonneveld MJ,Rijckborst V ,Zeuzem S ,et al. Presence of precore and core promoter mutants limits the probability of response to peginterferan in hepatitis B e antigen-positive chronic hepatitis B[J]. Hepatology ,2012, 56(1) :67-75.

引证文献2

二级引证文献2

肝脏
2015年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部